Want to see GPCR full AI Analyst Report?
GPCR Stock Chart & Stats
$49.92
-$1.68(-3.31%)
At close: 4:00 PM EDT
$49.92
-$1.68(-3.31%)
Day’s Range― - ―
52-Week Range$25.09 - $94.90
Previous CloseN/A
Volume655.41K
Average Volume (3M)1.28M
Market Cap
$1.96B
Enterprise Value$2.56B
Total Cash (Recent Filing)$1.34B
Total Debt (Recent Filing)$6.23M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Nov 18, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.03
Shares Outstanding71,309,860
10 Day Avg. Volume1,697,642
30 Day Avg. Volume1,277,048
Financial Highlights & Ratios
PEG Ratio-11.30
Price to Book (P/B)2.72
Price to Sales (P/S)0.00
P/FCF Ratio-18.23
Enterprise Value/Market Cap1.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.10K
Enterprise Value/Ebitda-12.06
Forecast
1Y Price Target
$108.46Price Target Upside117.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-1.67
Revenue Forecast (FY)$35.71M
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal leverage gives Structure financial flexibility while it funds clinical development, reducing refinancing pressure and interest-related constraints. The sizable positive equity base provides a stronger platform for sustaining operations and pursuing programs than a highly indebted balance sheet would.
Positive Clinical DataEarly ACCG-2671 results support the potential of Structure’s oral small-molecule approach, combining encouraging pharmacokinetics, initial biological activity, and no serious adverse events in the reported study. These findings inform ongoing dosing and further clinical development.
Oral GPCR PlatformA proprietary focus on orally delivered GPCR medicines gives Structure a defined platform strategy in metabolic disease, including obesity and cardiometabolic conditions. If development succeeds, oral candidates could broaden treatment options and support multiple programs from shared discovery capabilities.
Bears Say
Pre-Revenue ModelThe absence of commercial revenue means Structure currently lacks product sales to support operating expenses and validate its business model. Financial progress therefore remains dependent on successful clinical development, regulatory approval, and eventual commercialization of candidates.
Heavy Cash BurnPersistently negative operating and free cash flow indicates that clinical development requires substantial ongoing funding before revenue can ramp. Continued burn can reduce financial resources over time and leave the company reliant on external funding to maintain its programs.
Expanding LossesWidening net and operating losses show that Structure’s spending burden has grown substantially while revenue remains absent. This weak earnings trajectory can persist through late-stage trials, increasing the financial resources needed before any candidate produces recurring commercial returns.
Structure Therapeutics, Inc. Sponsored ADR News
GPCR FAQ
What was Structure Therapeutics, Inc. Sponsored ADR’s price range in the past 12 months?
Structure Therapeutics, Inc. Sponsored ADR lowest stock price was $25.09 and its highest was $94.90 in the past 12 months.
What is Structure Therapeutics, Inc. Sponsored ADR’s market cap?
Structure Therapeutics, Inc. Sponsored ADR’s market cap is $1.96B.
When is Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date?
Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date is Nov 18, 2026 which is in 40 days.
How were Structure Therapeutics, Inc. Sponsored ADR’s earnings last quarter?
Structure Therapeutics, Inc. Sponsored ADR released its earnings results on Aug 06, 2026. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.386 by -$0.104.
Is Structure Therapeutics, Inc. Sponsored ADR overvalued?
According to Wall Street analysts Structure Therapeutics, Inc. Sponsored ADR’s price is currently Undervalued.
Does Structure Therapeutics, Inc. Sponsored ADR pay dividends?
Structure Therapeutics, Inc. Sponsored ADR does not currently pay dividends.
What is Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate?
Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate is -0.33.
How many shares outstanding does Structure Therapeutics, Inc. Sponsored ADR have?
Structure Therapeutics, Inc. Sponsored ADR has 71,309,860 shares outstanding.
What happened to Structure Therapeutics, Inc. Sponsored ADR’s price movement after its last earnings report?
Structure Therapeutics, Inc. Sponsored ADR reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.386. Following the earnings report the stock price went up 0.988%.
Which hedge fund is a major shareholder of Structure Therapeutics, Inc. Sponsored ADR?
Currently, no hedge funds are holding shares in GPCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Structure Therapeutics, Inc. Sponsored ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$108.46 (117.27% Upside)
$108.46 (117.27% Upside)
Blogger Sentiment
Bullish
GPCR Sentiment 86%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 292.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 2.3%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.12%
12-Months-Change
Fundamentals
Return on Equity
-16.91%
Trailing 12-Months
Asset Growth
74.59%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Structure Therapeutics, Inc. Sponsored ADR
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
GPCR Stock 12 Month Forecast
Average Price Target
$108.46
▲(117.27% Upside)
Technical Analysis
Lexicon Pharmaceuticals
―
Viking Therapeutics
―
MBX Biosciences, Inc.
―
Septerna, Inc.
―
Kailera Therapeutics, Inc.
―
Ownership Overview
10.21% Insiders
26.20% Mutual Funds
46.69% Other Institutional Investors
15.39% Public Companies and
Individual Investors